Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Neoplasms × nimotuzumab × Clear all

Phase

Phase 3 1 Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Nasopharyngeal Carcinoma 4 Head and Neck Neoplasms 3 Uterine Cervical Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Nasopharyngeal Neoplasms 2 Esophageal Neoplasms 2 Stomach Neoplasms 1 Pancreatic Neoplasms 1 Neoplasms 1 Nasopharyngeal Diseases 1 Colorectal Neoplasms 1 Carcinoma 1

Interventions

Paclitaxel 19 Dexamethasone 16 Bevacizumab 16 Oxaliplatin 14 Docetaxel 14 Cyclophosphamide 12 Capecitabine 12 Gemcitabine 11 Sorafenib 10 Leucovorin 10 Fluorouracil 10 Carboplatin 10 Epoetin Alfa 9 pembrolizumab 8 Pemetrexed 8 Fentanyl 8 venetoclax 7 atezolizumab 7 Rivaroxaban 7 Prednisone 7 Drug Therapy 7 Doxorubicin 7 Anastrozole 7 Rituximab 6 Ondansetron 6 Morphine 6 Irinotecan 6 Denosumab 6 Cisplatin 6 Tranexamic Acid 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03413579 2021-08-25

CIMAHOPE

El Kendi Pharmaceuticals Manufacturing Company

Phase 3 Completed

Uterine Cervical Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡